L. Douglas

Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Christina M. Canil, Malcolm J. Moore, Eric Winquist et al. · Journal of Clinical Oncology · 2005 · 207 citations

Medicine, Oncology, Pharmacology +8

A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

Mary J. MacKenzie, Holger W. Hirte, Glenwood D. Goss et al. · Investigational New Drugs · 2005 · 67 citations

Medicine, Oncology, Pharmacology +14

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

Glenwood Goss, Hal W. Hirte, Wilson H. Miller et al. · Investigational New Drugs · 2005 · 48 citations

Pharmacy, Oncology, Pharmacotherapy +7

Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses

L. Douglas, Na Yi, Jennifer L. Davis et al. · Journal of Veterinary Pharmacology and Therapeutics · 2008 · 41 citations

Medicine, Ophthalmology, Veterinary Ophthalmology +16

A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129

Karen A. Gelmon, Ted Vandenberg, Lawrence Panasci et al. · Annals of Oncology · 2003 · 21 citations · Full text

Medicine, Oncology, Pharmacology +13